Selecta Biosciences, Inc. Banner Image

Selecta Biosciences, Inc. has reached its limit for free report views

Work for Selecta Biosciences, Inc.? Upgrade Your Profile and unlock all your annual reports.

Selecta Biosciences, Inc.

  • Ticker SELB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Selecta Biosciences, Inc. Logo Image
  • 11-50 Employees
  • Based in Watertown, Massachusetts
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well asMore restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.
Selecta Biosciences, Inc.

Most Recent Annual Report

Selecta Biosciences, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Selecta Biosciences, Inc. has reached its limit for free report views.

Older/Archived Annual Reports